ClinicalTrials.gg
RecruitingNCT06983678PRISM02Updated Nov 12, 2026

Neural Correlates and Behavioral Impact of Withdrawal-induced Hyperalgesia Among People Who Smoke With and Without Chronic Pain

An interventional study of Smoking as usual fMRI session and Abstinent fMRI session in Tobacco Use and Chronic Pain, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Duke University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Tobacco Use with a site in United States — 54 open to participants now, 65 under way, 1 of them phase 3. Tobacco Use · United States.

Planned enrollment
137th of 288
132 · median 120
Started
2025
with 22 others
No phase
233 of 313
40 open now
Primary completion
2030-03
later than 60 of 64 live
Registered
289th of 313
by date
Lead sponsor
7 of 313
Duke University

Among the 313 studies in Tobacco Use with a site in United States, this one is the 137th largest by planned enrollment of the 288 interventional ones that give a count, is one of 23 that started in 2025, is one of 233 with no phase, reaches primary completion later than 60 of the 64 other live ones, and was the 289th registered.

Tobacco Use

423 studies on the registry are indexed under Tobacco Use; 85 are open to participants now.

Browse Tobacco Use studies →

Open to participants now

54 of the 313 studies in Tobacco Use with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Tobacco Use studies recruiting now, 28 (55%) set no upper age limit and 19 (37%) stop at 75 or younger; 2 take children under 18; 28 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Tobacco Use with a site in United States, or all of them as a file.
02

Study summary

Individuals with chronic pain are more likely to smoke cigarettes and have more difficulty quitting smoking than the general population, in part because withdrawal from smoking can lead to temporary increases in pain. This research will examine how smoking withdrawal changes the way the brain processes pain, and whether these withdrawal-related changes interfere with the ability to stop smoking. The results of this research will provide important information that can be used to guide the development of interventions to help people with chronic pain who smoke cigarettes to quit smoking and improve their health.

Read the detailed description

Eligible participants will complete an initial in-person screening session in which eligibility is confirmed and baseline pain and smoking measures are collected, followed by a sensory testing and training session, in which participants are introduced to the mock MRI scanner and familiarized with the thermal pain stimulation and psychophysiological rating procedures. Participants will then complete two fMRI sessions using a within-subjects, crossover design, with one scan following 24-hrs abstinence from smoking, and the other following smoking as usual. Both fMRI sessions will be identical other than the smoking instructions prior to the scan. During each scan, participants will complete experience and provide ratings to painful heat stimuli. Before and after scanning, participants will complete measures of craving, withdrawal, and current pain level. After completion of the scanning sessions, participants will return to the lab for a baseline visit prior to beginning the abstinence test. During that session, they will have software installed on their smartphone for ecological momentary assessment (EMA), and they will be trained in the procedures for biochemical verification of abstinence. They will then complete 3 days of baseline EMA, during which participants are prompted at 5 random times throughout the day, and once in the evening, to answer questions about their pain, smoking urge, and recent smoking. They will then continue EMA while attempting to abstain from smoking during the 1-week abstinence test. During the abstinence test, each day of abstinence is reinforced with money using a descending schedule. Participants will provide breath samples over video during this week using equipment provided by the lab in order to verify abstinence from smoking. At the conclusion of the study, participants will return to the lab for a final visit to return all equipment.

03

Conditions studied

  • Tobacco Use
  • Chronic Pain
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. History of chronic non-cancer low back pain with duration ≥ 6 months OR no history of chronic pain;
  2. age 21-65;
  3. smoking of at least 10 cig/day for > 2 years;
  4. have an iPhone or Android smartphone capable of running the EMA software

Exclusion criteria

Exclusion Criteria:

  1. pain complaint specifically due to cancer, rheumatoid arthritis, or complex regional pain syndrome;
  2. actively taking steps to quit smoking;
  3. inability to attend all required experimental sessions;
  4. significant health problems, such as chronic hypertension, emphysema, seizure disorder, history of significant heart problems;
  5. conditions that would make MRI scanning unsafe (e.g., metal implants, claustrophobia)
  6. use of opioids within the past 90 days
  7. past year alcohol or substance use disorder
  8. positive urine test for illegal drugs (other than marijuana);
  9. daily use of alcohol or marijuana;
  10. lifetime history of psychotic disorder, or current unstable psychiatric disorder;
  11. regular use of non-cigarette tobacco products or electronic cigarettes;
  12. major surgery within the past 6 months or planned surgery within the timeframe of the study;
  13. breath alcohol level > 0.0 (participants failing for BAL will be allowed to rescreen once);
  14. recently quit smoking for > 3 days;
  15. pregnancy or planning to become pregnant;
  16. any factors that at the discretion of the investigators would adversely affect the participant or integrity of the study (e.g., ongoing legal action or disability claim regarding pain, uncontrolled psychiatric disorder, head/neck injury, use of certain medications)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Participants with chronic pain - Smoking as usual fMRI session first followed by Abstinent fMRI

    Participants with chronic pain randomized to complete a smoking as usual fMRI session followed by an Abstinent fMRI session.

    Behavioral: Smoking as usual fMRI session · Behavioral: Abstinent fMRI session

  • Experimental
    Participants with chronic pain - Abstinent fMRI session first followed by Smoking as usual fMRI

    Participants with chronic pain randomized to complete an Abstinent fMRI session followed by a smoking as usual fMRI session.

    Behavioral: Smoking as usual fMRI session · Behavioral: Abstinent fMRI session

  • Experimental
    Participants without chronic pain - Smoking as usual fMRI session first followed by Abstinent fMRI

    Participants without chronic pain randomized to complete a smoking as usual fMRI session followed by an Abstinent fMRI session.

    Behavioral: Smoking as usual fMRI session · Behavioral: Abstinent fMRI session

  • Experimental
    Participants without chronic pain - Abstinent fMRI session first followed by Smoking as usual fMRI

    Participants without chronic pain randomized to complete an Abstinent fMRI session followed by a smoking as usual fMRI session.

    Behavioral: Smoking as usual fMRI session · Behavioral: Abstinent fMRI session

Interventions

  • BehavioralSmoking as usual fMRI session

    Participants in this condition will continue smoking as usual prior to the fMRI session

  • BehavioralAbstinent fMRI session

    Participants in this condition will be asked to abstain from smoking or using any other tobacco products for 24 hours prior to the fMRI session

06

What researchers measure

Primary outcomes

  1. Pain intensity ratings to high heat vs neutral temperatures

    Participants will rate their current pain intensity following each of the heat stimulus blocks during the fMRI scans. Pain intensity is measured on a 0-10 visual analogue scale, with higher scores indicating greater pain.

    Time frame: Measured at each fMRI session (up to 1.5 hours)

  2. Activation of the inferior frontal gyrus (IFG)

    % signal change in response to the contrast of high heat vs rest will be extracted from right and left IFG

    Time frame: Measured at each fMRI session (up to 1.5 hours)

  3. Resting state functional connectivity with the IFG

    Fisher-Z transformed correlation maps of connectivity with the IFG will be evaluated within a subcortical mask including the caudate and thalamus

    Time frame: Measured at each fMRI session (up to 1.5 hours)

  4. Time to lapse

    The number of days of continuous, biochemically verified abstinence prior to smoking

    Time frame: Measured daily during the 1-week abstinence test

  5. Daily pain ratings

    Mean pain ratings during the initial days of abstinence will be examined as a function of chronic pain status, assessed at baseline

    Time frame: Measured with daily EMA prompts for 10 days

  6. Daily withdrawal symptoms

    Daily withdrawal symptoms will be assessed over EMA using the Minnesota Smoking Withdrawal Scale. Mean withdrawal symptoms during the initial days of abstinence will be examined as a function of chronic pain status, assessed at baseline

    Time frame: Measured with daily EMA prompts for 10 days

  7. Fluctuations in pain ratings vs smoking urge

    Fluctuations in pain ratings will be examined to determine their association with level of smoking urge

    Time frame: Measured 5 times per day with random EMA prompts for 10 days

  8. Fluctuations in pain ratings vs number of cigarettes smoked

    Fluctuations in pain ratings will be examined to determine their association with number of cigarettes smoked between each assessment.

    Time frame: Measured 5 times per day with random EMA prompts for 10 days

07

Study locations

1 of 1 sites recruiting
  • Duke North Pavilion
    Durham, North Carolina 27705, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2030, 52 months after the start.

Of 167 non-industry interventional studies with no phase under Tobacco Use, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 52 months is above that.

Counting every sponsor, half of 224 studies reached it within 16 months; a quarter within 5 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 21, 2025
StartActual
Nov 4, 2025
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and contact details
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06983678
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
May 21, 2025
Start date
Nov 4, 2025
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Research Coordinator
Contact
sweitzerlab@duke.edu
919-907-9955
Maggie Sweitzer, Ph.D.
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion